hi bluesky besties im back with another medical question... anyone here on #vraylar and can dish me the tea

Vraylar Patient Tips: 7 things you should know Easy-to-read patient tips for Vraylar covering how it works, benefits, risks, and best practices.

#Vraylar treats schizophrenia, bipolar disorder, and depression (add-on). Once-daily atypical antipsychotic with fewer metabolic effects and less sedation than older options. Common: restlessness, movement issues, nausea. Requires monitoring; avoid in elderly dementia.

We watch all this depressing news today and are grateful for the ads for anti-depression medication like #Vraylar. It’s all so well choreographed! 🥳

A green background with a white border. White text at the top says: 2025 Annual Report Below text says: The board voted to approve the 2025 Annual Report for the Oregon Legislature. The report outlines the board's activities, price trend analyses, and policy recommendations to improve drug affordability across Oregon. To the right is a screenshot of the yellow report cover with a photo of a family.

A green background with a white border. White text at the top says: 2025 Affordability Reviews. Below text says: Board members identified several top priority drugs that present significant affordability challenges for Oregonians: Cosentyx Creon Vraylar Trulicity Lantus SoloStar Their final vote will be at their January 21 meeting. Icons of an injection, pills, and a price tag with three dollar signs.

A green background with a white border. White text at the top says: Next Year. Below text says: The board is already preparing for 2026 affordability reviews, developing a preliminary list of 137 drug products for review based on 2024 data. To ensure patient voices are heard, a major outreach project will launch in spring of 2026 with community meetings in Salem, Redmond, Portland, and Beaverton, and online. An icon of the state of Oregon with hands raised inside. A speech bubble coming from the state with a pill bottle and a price tag with three dollar signs.

A green background with a white border. White text at the top says: Looking Ahead. White text below says: Next PDAB Meeting: January 21, 2026 at 8 am, Register for Zoom Link. Board members will vote on the final list of unaffordable drugs from their 2025 affordability reviews. A white icon of a calendar with the date January 21.

This Wednesday the #Oregon #PDAB met. Here are the highlights:
- Annual Report
- 2025 #Affordability Reviews
- Next Year's Plan

Next meeting: Jan 21, 2026 at 8 am. Zoom link at dfr.oregon.gov/pdab

#Cosentyx #Creon #Vraylar #Trulicity #LantusSoloStar #HealthPolicy

#Vraylar will kill you. Don't take it. #Abbie

Key Meeting + Program Updates All PDAB meetings will now begin at 8:00 AM (starting Aug 20) One board member shared a conflict due to owning pharmacies Ralph Magrish left his role as Executive Director. The search is on for a new leader: deadline to apply is July 28 Applications for a new PDAB member have closed and are under review

Affordability Review Discussion Migraine meds: Ajovy, Emgality, Nurtec, Ubrelvy Differences in how they work and how they’re given Prior approvals are often required (which can delay treatment)

Affordability Review Discussion Continued Vraylar: Used a lot by Medicaid patients for schizophrenia Entresto: A heart failure drug with no alternative Worries about higher prices hurting people of color Some say it’s already affordable with help programs

Looking Ahead Next PDAB Meeting: August 20, 2025 @ 8 AM Focus on migraine drugs first Board packets will be clearer, with key info up front Board wants better ways to define “affordability”

In this week's meeting, the #Oregon Prescription Drug Affordability Board (#PDAB) focused on program changes their first drug #AffordabilityReviews. Learn more in the slides →
Next meeting: August 20, 2025 @ 8 AM.
#HealthPolicySky #Migraines #Ajovy #Emgality #Nurtec #Ubrelvy #Vraylar #Entresto #OCAP

Do you take or have you taken: Vraylar? Generic: Cariprazine HCl. Therapy Class: Antipsychotics & Antimaic agents. Consider sharing your story with the Oregon Prescription Drug Affordability Board on July 16.

The Oregon Prescription Drug Affordability Board (PDAB) is reviewing high-cost drugs that may strain Oregon patients or our health care system. PDAB’s First Review Will Be Of: Vraylar (Cariprazine HCl ) Entresto (Sacubitril; Valsartan) Ajovy (Fremanezumab-vfrm) Emgality (Galcanezumab-gnlm) Nurtec (Rimegepant/ rimegepant sulfate) Ubrelvy (Ubrogepant)

Your Voice Matters! If you have taken any of these medications consider sharing your story at the July 16 PDAB meeting How to Share Your Experience Submit a comment - by July 14 at 9AM Speak at the meeting - sign up by July 15 at 9AM

The #Oregon Prescription Drug Affordability Board is reviewing #Vraylar (Generic: #CariprazineHCl) on July 16 starting at 9 AM.

If you or someone you know takes or has taken this medication, consider sharing your experience.

Public comment: dfr.oregon.gov/pdab/Pages/p...

#OCAP #HealthPolicy

Vraylar Patient Tips: 7 things you should know Easy-to-read patient tips for Vraylar covering how it works, benefits, risks, and best practices.

#Vraylar is an atypical antipsychotic that is used to treat schizophrenia and bipolar I disorder. Vraylar is usually well-tolerated and less likely than some other antipsychotics to cause elevations in blood sugar or total cholesterol levels, sedation, or weight gain.

What are 6 Vraylar side effects you need to be aware of? Official answer: Key Points Vraylar (cariprazine) is a once-daily oral medication that may be used to treat bipolar disorder...

#Vraylar: a once-daily oral medication for bipolar disorder, depression, or schizophrenia. Common side effects include movement disorders, stomach problems; sleep problems, and increased appetite and weight gain.

Wanna see some fucked up stuff in the world of #mentalhealth: check the price for this drug. 30 pills. 1 month: #vraylar
In a time when psychiatrists don’t take insurance and charge $250 a session. @potus @GovofCO